COMMUNIQUÉS West-GlobeNewswire

Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
09/08/2018
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
09/08/2018
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over 20 years Top-line [...]
Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results
09/08/2018
Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage [...]
Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
Company reports 80% growth in total quarterly revenue year-over-year Multiple clinical and regulatory milestones achieved for Viveve ® System ENGLEWOOD, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Viveve Medical Inc. ( [...]
TearLab Corporation Reports Second Quarter and First Half 2018 Financial Results
09/08/2018
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the second quarter ended June 30, 2018. All dollar [...]
Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
SANTA MONICA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, [...]
CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for [...]
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress
09/08/2018
-- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018 and discuss with regulatory authorities next steps for a registrational pathway based on positive Phase [...]
Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights
09/08/2018
MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty [...]
Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring
09/08/2018
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of “Autologous adipose-derived stromal vascular [...]
RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
09/08/2018
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
Vaccinex Announces Pricing of Initial Public Offering
09/08/2018
ROCHESTER, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and [...]
Healthwise Announces Jay Reynolds as Chief Technology Officer
09/08/2018
BOISE, Idaho, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Healthwise, a leader in evidence-based health education, technology and services, announced that Jay Reynolds has assumed the position of Chief Technology Officer (CTO). [...]
Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results
09/08/2018
WESTLAKE VILLAGE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for [...]
Medtronic Begins Pilot Study of Investigational Extravascular ICD System
09/08/2018
Chronic Study Evaluating New ICD System Designed to Deliver Pacing and Defibrillation Therapy Via a Lead Placed Under the Sternum, Outside the Heart and Veins DUBLIN - August 9, 2018 - Medtronic plc (NYSE:MDT) today [...]
Aptevo Therapeutics Reports Second Quarter 2018 Financial Results
09/08/2018
Achieves Record IXINITY ® Net Revenue with 94% Increase in Year-Over-Year Quarterly Revenue Publishes and Presents New Data on Multiple ADAPTIR™ Bispecific Candidates Showing Robust Immune System Engagement and T-cell [...]
BioStem Technologies, Inc. (BSEM) Launches New Subsidiary to Engage in the Processing and Supply of Regenerative Tissue Products
09/08/2018
Pompano Beach, FL, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), BioStem Technologies, Inc. is a global life sciences corporation, providing innovative [...]
Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage
09/08/2018
BUFFALO, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 8 August 2018
09/08/2018
Bagsværd, Denmark, 9 August 2018 - This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 [...]

Pages